GIANT BIOGENE (02367) Surges Over 5% as Injectable Recombinant Collagen and Sodium Hyaluronate Complex Solution Gains Approval

Stock News01-16

GIANT BIOGENE (02367) rose more than 5%. As of the time of writing, the stock was up 5.38%, trading at HK$37.84, with a turnover of HK$16.5135 million. On January 15, the company announced that its wholly-owned subsidiary, Shaanxi GIANT BIOGENE Technology Co., Ltd., received a Medical Device Registration Certificate from China's National Medical Products Administration for its recombinant type I α1 collagen and sodium hyaluronate complex solution product. The product, primarily composed of recombinant collagen and sodium hyaluronate, is intended for injection into the dermis to improve facial cheek smoothness. This product is the world's first implantable formulation of a recombinant collagen and sodium hyaluronate complex solution approved specifically for improving cheek smoothness, having officially passed a joint review by medical device and pharmaceutical regulatory authorities. CICC commented that it views the approval favorably, as it is expected to further expand the company's aesthetic product portfolio, demonstrating its leading technological R&D capabilities. The institution noted that the company is expected to steadily advance the product's launch, promotion, and market distribution, aiming to provide differentiated solutions through a diverse product mix, comprehensive channel network, and refined brand operations, thereby continuously strengthening its leading market position in the health and beauty sectors.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1184993247?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-16 09:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1184993247","market":"sg","top_or_hot":-1,"title":"GIANT BIOGENE (02367) Surges Over 5% as Injectable Recombinant Collagen and Sodium Hyaluronate Complex Solution Gains Approval","media":"Stock News","content":"<p>GIANT BIOGENE (02367) rose more than 5%. As of the time of writing, the stock was up 5.38%, trading at HK$37.84, with a turnover of HK$16.5135 million.\nOn January 15, the company announced that its wholly-owned subsidiary, Shaanxi GIANT BIOGENE Technology Co., Ltd., received a Medical Device Registration Certificate from China's National Medical Products Administration for its recombinant type I α1 collagen and sodium hyaluronate complex solution product.\nThe product, primarily composed of recombinant collagen and sodium hyaluronate, is intended for injection into the dermis to improve facial cheek smoothness.\nThis product is the world's first implantable formulation of a recombinant collagen and sodium hyaluronate complex solution approved specifically for improving cheek smoothness, having officially passed a joint review by medical device and pharmaceutical regulatory authorities.\nCICC commented that it views the approval favorably, as it is expected to further expand the company's aesthetic product portfolio, demonstrating its leading technological R&D capabilities.\nThe institution noted that the company is expected to steadily advance the product's launch, promotion, and market distribution, aiming to provide differentiated solutions through a diverse product mix, comprehensive channel network, and refined brand operations, thereby continuously strengthening its leading market position in the health and beauty sectors.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GIANT BIOGENE (02367) Surges Over 5% as Injectable Recombinant Collagen and Sodium Hyaluronate Complex Solution Gains Approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGIANT BIOGENE (02367) Surges Over 5% as Injectable Recombinant Collagen and Sodium Hyaluronate Complex Solution Gains Approval\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-01-16 09:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>GIANT BIOGENE (02367) rose more than 5%. As of the time of writing, the stock was up 5.38%, trading at HK$37.84, with a turnover of HK$16.5135 million.\nOn January 15, the company announced that its wholly-owned subsidiary, Shaanxi GIANT BIOGENE Technology Co., Ltd., received a Medical Device Registration Certificate from China's National Medical Products Administration for its recombinant type I α1 collagen and sodium hyaluronate complex solution product.\nThe product, primarily composed of recombinant collagen and sodium hyaluronate, is intended for injection into the dermis to improve facial cheek smoothness.\nThis product is the world's first implantable formulation of a recombinant collagen and sodium hyaluronate complex solution approved specifically for improving cheek smoothness, having officially passed a joint review by medical device and pharmaceutical regulatory authorities.\nCICC commented that it views the approval favorably, as it is expected to further expand the company's aesthetic product portfolio, demonstrating its leading technological R&D capabilities.\nThe institution noted that the company is expected to steadily advance the product's launch, promotion, and market distribution, aiming to provide differentiated solutions through a diverse product mix, comprehensive channel network, and refined brand operations, thereby continuously strengthening its leading market position in the health and beauty sectors.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999004311.SGD","symbol_name":"Nikko AM Shenton Emerging Enterprise Discovery Fund SGD","start_time":0,"source_url":"","article_id":"1184993247","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1184993247","pubTimestamp":1768528035,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"GIANT BIOGENE (02367) rose more than 5%. As of the time of writing, the stock was up 5.38%, trading at HK$37.84, with a turnover of HK$16.5135 million. On January 15, the company announced that its...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SG9999004311.SGD":"Nikko AM Shenton Emerging Enterprise Discovery Fund SGD","02367":"巨子生物","BK1207":"个人用品","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC"},"translate_title":"巨人生物基因(02367)大涨超5%，注射用重组胶原蛋白和透明质酸钠复合液获批","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02367":1},"content_text":"GIANT BIOGENE (02367) rose more than 5%. As of the time of writing, the stock was up 5.38%, trading at HK$37.84, with a turnover of HK$16.5135 million.\nOn January 15, the company announced that its wholly-owned subsidiary, Shaanxi GIANT BIOGENE Technology Co., Ltd., received a Medical Device Registration Certificate from China's National Medical Products Administration for its recombinant type I α1 collagen and sodium hyaluronate complex solution product.\nThe product, primarily composed of recombinant collagen and sodium hyaluronate, is intended for injection into the dermis to improve facial cheek smoothness.\nThis product is the world's first implantable formulation of a recombinant collagen and sodium hyaluronate complex solution approved specifically for improving cheek smoothness, having officially passed a joint review by medical device and pharmaceutical regulatory authorities.\nCICC commented that it views the approval favorably, as it is expected to further expand the company's aesthetic product portfolio, demonstrating its leading technological R&D capabilities.\nThe institution noted that the company is expected to steadily advance the product's launch, promotion, and market distribution, aiming to provide differentiated solutions through a diverse product mix, comprehensive channel network, and refined brand operations, thereby continuously strengthening its leading market position in the health and beauty sectors.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1184993247","isCrawlerRequest":true}